1.	Drug-eluting Bead in Hepatocellular Carcinoma Phase: Phase IV Type: Treatment Status: Enrolling by invitation Age: 20 and over Sponsor: Other Protocol IDs: Biocompatible-Korea, NCT01332669
2.	Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 19 and over Sponsor: Other Protocol IDs: H08-02833, NCT01116635
3.	Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Phase: Phase II Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI, Other Protocol IDs: CDR0000456493, P30CA006973, JHOC-J0516, HOC-05042805, NCT00293397
4.	Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: J08110, NCT00844883
5.	A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12918, 2008-005056-24, NCT00855218